This Italian study on exposure to radiofrequency radiation and cancer in rats was started in 2005. It was a whole life-span study including 2448 animals. They were divided into 4 groups; 0 exposure (control group), 5 V/m, 25 V/m or 50 V/m. It has now been published and interestingly the results are similar as in the NTP study.
A statistically significant increase in the incidence of heart Schwannomas was observed in treated male rats at the highest dose (50 V/m). Furthermore, an increase in the incidence of heart Schwann cells hyperplasia was observed in treated male and female rats at the highest dose (50 V/m), although this was not statistically significant. An increase in the incidence of malignant glial tumors was observed in treated female rats at the highest dose (50 V/m), although not statistically significant.
The RI findings on far field exposure to RFR are consistent with and reinforce the results of the NTP study on near field exposure, as both reported an increase in the incidence of tumors of the brain and heart in RFR-exposed Sprague-Dawley rats. These tumors are of the same histotype of those observed in some epidemiological studies on cell phone users. These experimental studies provide sufficient evidence to call for the re-evaluation of IARC conclusions regarding the carcinogenic potential of RFR in humans.
Considering this study, the NTP study, increasing incidence of glioma, and human epidemiology studies showing increased risk for glioma and vestibular schwannoma (acoustic neuroma) for persons using wireless phones it is time for International Agency for Research on Cancer (IARC) to make a new risk assessment. The results indicate that radiofrequency radiation should be a Group 1 carcinogen to humans (sufficient evidence).
This study is now under peer review during March 26 to 28, 2018; the reports can be found here (NTP TR 595; rats) and here (NTP TR 596; mice). It has been able to submit comments and our views can be found here.
Our overall evaluation of levels of evidence of carcinogenic activity are:
Glioma: Clear evidence
Meningioma: Equivocal evidence
Vestibular schwannoma (acoustic neuroma): Clear evidence
Pituitary tumor (adenoma): Equivocal evidence
Thyroid cancer: Some evidence
Malignant lymphoma: Equivocal evidence
Skin (cutaneous tissue): Equivocal evidence
Multi-site carcinogen: Some evidence
Based on the IARC preamble to the monographs, RF radiation should be classified as Group 1: The agent is carcinogenic to humans.
’This category is used when there is sufficient evidence of carcinogenicity in humans. Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent acts through a relevant mechanism of carcinogenicity.’ (http://monographs.iarc.fr/ENG/Preamble/currentb6evalrationale0706.php)
A recent article describes increasing incidence of the most malignant type of brain tumor, glioblastoma multiforme (GBM) in England during 1995-2015. The number of patients increased from 2.4 to 5.0 per 100,000 during that time period. In total the yearly increase was from 983 to 2,531 patients, thus a substantial number. The incidence of low-grade glioma decreased but was stabilized from 2004, see figure 2. Thus the increasing incidence cannot be explained by low-grade glioma transforming to high-grade (GBM). The authors conclude that a general environmental factor must be the cause.
The increasing incidence is most pronounced for GBM in temporal or frontal parts of the brain, see figure 6. That is parts with highest exposure to radiofrequency radiation from the handheld wireless phone.
The increasing incidence of GBM was seen in all age groups but was most pronounced in those aged more than 55 years.
We published incidence data on brain tumours for the time period 1998-2015 based on the Swedish Cancer Register. In the age group 60-79 years the yearly incidence of high-grade glioma increased statistically significant in men with +1.68% (+0.39, +2.99 %) (n = 2,275) and in women with +1.38% (+0.32, +2.45%) (n = 1,585), see figures. Few patients were diagnosed in the age group 80+ yielding analysis less meaningful. High-grade glioma includes astrocytoma grades III and IV. Astrocytoma grade IV is the same as glioblastoma multiforme (GBM) with bad prognosis, survival about one year or less.
Our results are similar to those now published from England. All results are in agreement with wireless phones (mobile phones and cordless phones) causing glioma.